JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Community-based Intervention Effects on Older Adults' Physical Activity

  NCT03326141

  Conditions:   Exercise;   Physical Activity;   Accidental Fall;   Motivation;   Older Adults
  Interventions:   Behavioral: Otago Exercise Program;   Device: Physical activity monitors (e.g., Fitbit);   Behavioral: Interpersonal Behavior Change Strategies;   Behavioral: Intrapersonal Behavior Change Strategies;   Other: Information about Health and Wellness
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Institute of Nursing Research (NINR)
  Recruiting
• Traumatic Nightmares Treated by NightWare (To Arouse Not Awaken)

  NCT04040387

  Conditions:   Stress Disorders, Post-Traumatic;   Combat Disorders;   Ptsd;   Nightmare;   Nightmares, REM-Sleep Type;   Nightmare Disorder With Associated Non-Sleep Disorder
  Interventions:   Device: NightWare Therapeutic System;   Device: Sham NightWare
  Sponsors:   NightWare;   Minneapolis Veterans Affairs Medical Center
  Recruiting
• Problem-Solving Therapy for Depressive Symptoms and Quality of Life in Stroke Survivor-Caregiver Dyads

  NCT04035681

  Conditions:   Stroke;   Quality of Life;   Depression
  Interventions:   Behavioral: Problem-Solving Therapy;   Other: Stroke-Related Health Education
  Sponsors:   Allina Health System;   University of Minnesota, MN
  Recruiting
• Cf-DNA Assay During Treatment of Acute Rejection

  NCT04019353

  Conditions:   Kidney Transplant Failure and Rejection;   Kidney Transplant; Complications;   Kidney Transplant Rejection;   Transplant; Complication, Rejection;   Transplant Dysfunction
  Intervention:   Genetic: cf-DNA Collection
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Validation of Bladder Health Instrument for Evaluation in Women

  NCT04016298

  Condition:   Lower Urinary Tract Symptoms
  Intervention:  
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   University of California, San Diego;   University of Pennsylvania;   Yale University;   University of Michigan;   University of Illinois at Chicago;   Loyola University Chicago;   University of Alabama at Birmingham;   Washington University School of Medicine
  Recruiting
• Allogeneic Skin Grafting

  NCT04015947

  Condition:   GVHD
  Intervention:   Device: CelluTome® Epidermal Harvesting System
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Positive Affect Treatment (PAT) to Target Reward Mechanisms in Anorexia Nervosa

  NCT04007900

  Conditions:   Anorexia Nervosa;   Anorexia
  Intervention:   Behavioral: Positive Affect Treatment
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Pilot Phase for an Acute Evaluation of a Non-Implantable Electrical Continence Device

  NCT04001426

  Condition:   Urinary Bladder, Overactive
  Intervention:   Device: The FemPulse System
  Sponsor:   FemPulse Corporation
  Recruiting
• Hepatic Energy Fluxes in NASH and NAS Patients

  NCT03997422

  Conditions:   NASH - Nonalcoholic Steatohepatitis;   NAS;   Overweight or Obesity;   Weight Loss;   Bariatric Surgery Candidate
  Intervention:   Procedure: Vertical Sleeve Gastrectomy (VSG)
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer

  NCT03981705

  Conditions:   TN ER-/PR-/HER2- Breast Cancer;   Triple Negative Breast Cancer;   HER2-positive Breast Cancer;   ERany/PRany/HER2+ Breast Cancer
  Intervention:   Radiation: Standard Trimodality Breast Imaging
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Ketamine and Prolonged Exposure in PTSD

  NCT03960658

  Condition:   Post-traumatic Stress Disorder
  Intervention:   Drug: ketamine-enhanced prolonged exposure
  Sponsor:   Minneapolis Veterans Affairs Medical Center
  Recruiting
• Low Sulfur Fecal Transplant for Ulcerative Colitis

  NCT03948919

  Condition:   Ulcerative Colitis
  Interventions:   Drug: Fecal microbiota;   Other: Placebo
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

  NCT03942653

  Condition:   Salivary Gland Carcinoma
  Interventions:   Drug: Goserelin Acetate;   Drug: Pembrolizumab
  Sponsors:   Big Ten Cancer Research Consortium;   Merck Sharp & Dohme Corp.;   TerSera Therapeutics
  Recruiting
• The MOMENTUM Study (Monitoring Maternal Emergency Navigation and Triage on Mfangano

  NCT03942536

  Conditions:   Pregnancy;   Neonatal Care;   Emergency Care
  Intervention:   Other: Focus Group Discussion
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Maseno University
  Recruiting
• The Effect of Vitamin C on Wound Healing In Mandibular Fracture Patients

  NCT03938584

  Conditions:   Vitamin C Deficiency;   Smoking;   Surgery;   Surgery--Complications;   Wound;   Wound Complication;   Wound Infection;   Wound Dehiscence;   Wound of Skin;   Mandible Fracture;   Mandible Open Fracture;   Mandible Closed Fracture;   Mandibular Fractures;   Ascorbic Acid Deficiency;   Oxidative Stress;   Inflammation
  Interventions:   Dietary Supplement: Vitamin C;   Other: Placebo
  Sponsors:   Hennepin Healthcare Research Institute.;   Regions Hospital;   University of Minnesota, MN
  Recruiting
• Training for Health Professionals In Tanzania

  NCT03923582

  Conditions:   Health Knowledge, Attitudes, Practice;   Training
  Intervention:   Behavioral: Health Curriculum Training
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Muhimbili University of Health and Allied Sciences;   Johns Hopkins University
  Recruiting
• The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer

  NCT03921658

  Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
  Intervention:  
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   United States Department of Defense
  Recruiting
• Adoptive Transfer of Haploidentical NK Cells and N-803

  NCT03899480

  Conditions:   Hiv;   HIV Infections;   Immune Deficiency
  Intervention:   Biological: Haploidentical Natural Killer (NK) Cells
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• The DEtermining Statin Intolerance FOr Rosuvastatin (DESIFOR) Trial

  NCT03889314

  Conditions:   Cardiovascular Risk Factor;   Cardiovascular Diseases;   Adverse Effect
  Interventions:   Drug: Rosuvastatin 20mg;   Other: Placebo
  Sponsor:   Minneapolis Heart Institute Foundation
  Recruiting
• Immunologic Effects of Radioembolization of Primary and Secondary Liver Malignancies

  NCT03889093

  Conditions:   Hepatocellular Carcinoma;   Secondary Malignant Neoplasm of Liver
  Intervention:   Other: Yttrium-90
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Advanced Reperfusion Strategies for Refractory Cardiac Arrest

  NCT03880565

  Conditions:   Cardiac Arrest;   Extracorporeal Membrane Oxygenation Complication;   Ventricular Fibrillation;   Pulseless Ventricular Tachycardia;   Out-Of-Hospital Cardiac Arrest
  Interventions:   Device: Early Extracorporeal Membrane Oxygenation (ECMO) Facilitated Resuscitation;   Device: Standard Advanced Cardiac Life Support (ACLS) Resuscitation
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Validation of Readiband™ Actigraph and Associated Sleep/Wake Classification Algorithms

  NCT03877861

  Conditions:   Glioma;   Glioblastoma
  Intervention:   Device: Readiband Sleep Tracking
  Sponsor:   Allina Health System
  Recruiting
• Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia

  NCT03852992

  Conditions:   Male Pattern Hair Loss;   Androgenetic Alopecia;   Male Pattern Baldness
  Interventions:   Drug: Post-Laser Minoxidil 2%;   Drug: At-Home Minoxidil 5%;   Device: Laser;   Drug: Post-laser 5mg minoxidil;   Drug: Post-laser 10mg minoxidil;   Drug: Post-laser 20mg minoxidil
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Treating Smokers With Mental Illness

  NCT03822416

  Conditions:   Smoking Cessation;   Cigarette Smoking;   Schizophrenia;   Psychotic Disorders;   Major Depressive Disorder;   Bipolar Disorder I;   Bipolar II Disorder;   Mental Illness
  Interventions:   Drug: Nicotine patch;   Drug: Nicotine lozenge;   Behavioral: Therapy;   Other: Information
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Hennepin County Medical Center, Minneapolis;   Brown University
  Recruiting
• Intra-Portal Alone Versus Intra- and Extra-Portal Transplantation of Pancreatic Islets After Total Pancreatectomy for Chronic Pancreatitis

  NCT03779139

  Conditions:   Chronic Pancreatitis;   Diabetes Mellitus;   Islet Cell Transplantation
  Interventions:   Procedure: Intrahepatic islets and islets in the omental pouch;   Procedure: Intrahepatic islets alone;   Other: Normal Volunteers
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Scaling and Root Planing (SRP) With and Without Minocycline HCl Microspheres, 1 mg

  NCT03762915

  Conditions:   SRP;   Minocycline HCl Microspheres;   Biomarkers
  Intervention:   Drug: minocycline HCl microspheres
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Bausch Health Companies, INC.
  Recruiting
• Isometric Intervention for Lateral Elbow Tendinopathy

  NCT03756155

  Conditions:   Lateral Elbow Tendinopathy;   Elbow Pain;   Elbows Tendonitis;   Elbow Sprain;   Elbow Injury
  Intervention:   Procedure: isometric intervention
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Laryngeal Vibration for Spasmodic Dysphonia

  NCT03746509

  Condition:   Spasmodic Dysphonia
  Interventions:   Device: Laryngeal Vibration (Treatment);   Device: Laryngeal Vibration (Comparator)
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures

  NCT03744728

  Condition:   Bloodstream Infection
  Interventions:   Diagnostic Test: Accelerate PhenoTest™ BC kit;   Diagnostic Test: Standard of Care
  Sponsor:   Accelerate Diagnostics, Inc.
  Recruiting
• Ultrasound Treatment of Rheumatoid Arthritis

  NCT03690466

  Condition:   Rheumatoid Arthritis
  Interventions:   Device: Study device treatment;   Device: Sham device treatment
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Spectroscopic Magnetic Resonance Imaging of Glioma

  NCT03677999

  Condition:   Brain Tumor-Glioma
  Intervention:   Diagnostic Test: MEGA-PRESS sequence Magnetic Resonance Spectroscopy
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Women's-Specific Footwear With Prosthetic Feet

  NCT03673371

  Conditions:   Lower Limb Amputation Below Knee (Injury);   Lower Limb Amputation Above Knee (Injury)
  Intervention:   Other: Questionnaire
  Sponsors:   Minneapolis Veterans Affairs Medical Center;   United States Department of Defense
  Recruiting
• Evaluation of Diaphragm Movement After an Interscalene Block

  NCT03636542

  Condition:   Phrenic Nerve Paralysis
  Interventions:   Drug: liposomal bupivacaine;   Drug: bupivacaine
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• mGlide RCT: A Clinical Glide Path To Close the Guideline-to-Practice Gap In HTN Management

  NCT03612271

  Condition:   Hypertension
  Intervention:   Behavioral: mGlide
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Heart, Lung, and Blood Institute (NHLBI)
  Recruiting
• Improving Self-Efficacy, Resolving Inflammaging Allo HSCT Survivors in Personal Training

  NCT03609203

  Condition:   Allogeneic HCT Survivors
  Interventions:   Other: 10 Weeks of Strength Trailing;   Other: Group Nutrition Discussion: week 1, week 5 and week 10
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Pec Infiltration With Liposomal Bupivacaine for Breast Surgery

  NCT03599635

  Condition:   Acute Pain
  Interventions:   Drug: liposomal bupivacaine;   Drug: Bupivacaine
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

  NCT03587831

  Condition:   NASH - Nonalcoholic Steatohepatitis
  Interventions:   Procedure: Vertical Sleeve Gastrectomy;   Behavioral: Lifestyle Modification Counseling
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Liposome Bupivacaine Interscalene Total Shoulder

  NCT03587636

  Condition:   Acute Pain
  Interventions:   Drug: liposome bupivacaine;   Drug: Bupivacaine
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Liposome Bupivacaine in Interscalene Block for Rotator Cuff Repair

  NCT03587584

  Condition:   Acute Pain
  Interventions:   Drug: liposomal bupivacaine;   Drug: Bupivacaine
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Brief Motivational Interviewing (BMI)

  NCT03571958

  Condition:   Motivational Interviewing, BMI, OHI
  Intervention:   Behavioral: BMI
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Splenic Embolization for Portal Hypertension

  NCT03532750

  Condition:   Portal Hypertension
  Interventions:   Device: Particle;   Device: Coil
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Exparel PK and Breast Milk Excretion

  NCT03526419

  Condition:   Milk Expression, Breast
  Intervention:   Drug: Bupivacaine liposome
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Peri-Incisional Drug Injection in Lumbar Spine Surgery

  NCT03513445

  Conditions:   Lumbar Disc Herniation;   Degenerative Disc Disease;   Spondylolisthesis
  Interventions:   Drug: Morphine;   Drug: Epinephrine;   Drug: naropin
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Role of CGMS Usage in Predicting Risk for Hypoglycemia

  NCT03481530

  Conditions:   Type 2 Diabetes Mellitus;   Hypoglycemia
  Intervention:   Device: Continuing Glucose Monitor System
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa

  NCT03414112

  Condition:   Anorexia Nervosa
  Intervention:   Biological: Intranasal oxytocin
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Klarman Foundation
  Recruiting
• Post C-Section Pain Control Using EXPAREL

  NCT03377595

  Condition:   Pain, Postoperative
  Intervention:   Drug: Exparel
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Safety and Feasibility of Imaging at 10.5 Tesla

  NCT03346707

  Condition:   Healthy
  Intervention:   Device: 10.5 Tesla
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

  NCT03346668

  Conditions:   Scarring Alopecia;   Frontal Fibrosing Alopecia;   Lichen Planopilaris;   Central Centrifugal Cicatricial Alopecia;   Central Centrifugal Scarring Alopecia
  Intervention:   Drug: Topical gabapentin
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Vitamin C and Septic Shock

  NCT03338569

  Conditions:   Septic Shock;   Sepsis
  Interventions:   Drug: Vitamin C;   Drug: Placebo
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Developement of Upper Limb Motor Scale

  NCT03328468

  Condition:   Stroke
  Intervention:   Other: Breathing Exercise
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Oral Cell DNA Adducts in Smokers

  NCT03285893

  Condition:   Lung Cancer
  Intervention:   Other: oral cell DNA adducts
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   University of Hawaii
  Recruiting
• e-Cigarette - DNA Adducts

  NCT03284632

  Conditions:   Smoking;   Cigarette Smoking;   Electronic Cigarettes
  Intervention:  
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Institutes of Health (NIH)
  Recruiting
• Neural Correlates of Reward and Symptom Expression in Anorexia Nervosa

  NCT03275545

  Condition:   Anorexia Nervosa
  Intervention:   Other: No intervention
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin

  NCT03259581

  Conditions:   Hepatocellular Carcinoma;   Bilirubinemia
  Intervention:   Combination Product: Transarterial chemoembolization
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• High-Intensity Aerobic Lifelong Training--AF

  NCT03241433

  Condition:   Atrial Fibrillation
  Interventions:   Other: High intensity interval training;   Other: Moderate intensity continuous training;   Other: No Exercise
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int

  NCT03213964

  Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
  Interventions:   Biological: FATE-NK100;   Drug: Interleukin-2
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Leg Exercise During ECMO

  NCT03135210

  Condition:   Refractory Respiratory Failure
  Interventions:   Other: Open-Chain Leg Exercise;   Device: Closed-Chain Leg Exercise
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Personalized Smoking Cessation Tool Based on Patient Lung CT Image

  NCT03087617

  Condition:   Smoking Cessation
  Interventions:   Device: Imbio Smoking Cessation Report;   Behavioral: Smoking Cessation Counseling;   Other: Usual Care
  Sponsors:   Imbio;   National Cancer Institute (NCI);   University of Michigan;   Mayo Clinic;   HealthPartners Institute;   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML

  NCT03081780

  Conditions:   Refractory Acute Myelogenous Leukemia;   Relapsed Acute Myelogenous Leukemia
  Intervention:   Biological: FATE-NK100
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Circuit-Based Deep Brain Stimulation for Parkinson's Disease; Udall Project 1 Aim 2 and 3

  NCT03079037

  Condition:   Parkinson Disease
  Intervention:   Device: Stimulation
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Epidural Stimulation After Neurologic Damage

  NCT03026816

  Conditions:   Spinal Cord Injuries;   Paraplegia, Complete
  Intervention:   Device: Epidural Spinal Cord Stimulation
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Minnesota Office of Higher Education;   Minneapolis Veterans Affairs Medical Center;   Hennepin Healthcare Research Institute.;   Hennepin County Medical Center, Minneapolis
  Recruiting
• Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

  NCT03019666

  Conditions:   Multiple Myeloma;   Non-Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma;   Mantle-Cell Lymphoma;   Follicular Lymphoma;   Indolent B Cell Lymphoma;   Primary Mediastinal Lymphoma;   Lymphoplasmacytic Lymphoma
  Intervention:   Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)

  NCT03005379

  Condition:   Clostridium Difficile Infection
  Interventions:   Drug: Fecal Microbiota Therapy (FMT);   Drug: Placebo
  Sponsor:   VA Office of Research and Development
  Recruiting
• Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

  NCT03001323

  Condition:   Diabetes Mellitus
  Interventions:   Drug: Degludec;   Drug: Standard long-acting
  Sponsor:   Hennepin Healthcare Research Institute.
  Recruiting
• Glucobrassicin-Brussel Sprout Effect on D10 Phe Metabolism

  NCT02999399

  Condition:   Smoking
  Interventions:   Other: Brussel Sprouts;   Drug: Deuterated Phenanthrene
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT

  NCT02989844

  Conditions:   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome (MDS)
  Intervention:   Drug: N-803
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Graded Motor Imagery for Women at Risk for Developing Type I CRPS Following Closed Treatment of Distal Radius Fractures

  NCT02957240

  Conditions:   Musculoskeletal Pain;   Fractures, Closed;   Distal Radius Fracture;   Complex Regional Pain Syndromes
  Interventions:   Behavioral: Standard Care;   Behavioral: Motor Representation Techniques
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   American Hand Therapy Foundation;   Fairview Health Services
  Recruiting
• Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

  NCT02930889

  Condition:   Benign Prostatic Hyperplasia
  Intervention:   Device: Prostate Artery Embolization
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• The Residential Care Transition Module

  NCT02915939

  Conditions:   Alzheimer Disease;   Dementia
  Intervention:   Behavioral: The Residential Care Transition Module
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Johns Hopkins University;   NYU Langone Health;   Benjamin Rose Institute;   Emory University
  Recruiting
• Technical Development of Multi-Parametric Renocerebral MRI

  NCT02831335

  Condition:   Aging
  Interventions:   Other: MRI;   Other: Group 4
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity

  NCT02798679

  Condition:   Cardiotoxicity
  Intervention:  
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Effect of Exercise on Perinatal Depression

  NCT02791932

  Conditions:   Pregnancy;   Postpartum Period;   Depression
  Intervention:   Behavioral: Exercise
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Cerebral Responses to Insulin Induced Hypoglycemia

  NCT02747680

  Conditions:   Type 1 Diabetes;   Healthy;   Hypoglycemia Unawareness
  Intervention:   Other: hypoglycemia (low blood sugar) in MRI
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• The LoBAG Diet and Type 2 Diabetes Mellitus

  NCT02717078

  Condition:   Type 2 Diabetes Mellitus
  Intervention:   Other: Diet Therapy
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Anti-inflammatory Therapy to Improve Outcomes After TPIAT

  NCT02713997

  Condition:   Pancreatitis, Chronic; Diabetes; Transplant
  Interventions:   Drug: etanercept;   Drug: Alpha 1-Antitrypsin
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease

  NCT02636283

  Condition:   Peripheral Arterial Disease
  Interventions:   Drug: Entresto;   Drug: Placebo group
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   American Heart Association
  Recruiting
• Bartonella in Liver Transplant Patients

  NCT02595710

  Conditions:   Cryptogenic Cirrhosis;   Cryptogenic Chronic Hepatitis
  Interventions:   Other: skin punch biopsy collection;   Other: Blood collection;   Other: Urine sample collection
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Pushing Spatiotemporal Limits for 4D Flow MRI and Dynamic MRA in the Brain at Ultra-High Field

  NCT02576743

  Condition:   Stroke
  Intervention:   Device: 7 Tesla MRI
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Accelerated Contrast-Enhanced High Resolution Whole Heart Cardiac MRI

  NCT02550366

  Condition:   Cardiac Disease
  Intervention:   Drug: MRI Contrast
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Beta-blockers in Pulmonary Arterial Hypertension

  NCT02507011

  Condition:   Pulmonary Arterial Hypertension
  Interventions:   Drug: Carvedilol;   Drug: Placebo
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Correlation Analysis Between Brain Lesions and Sensorimotor Impairments in Individuals With Stroke (Preliminary Study)

  NCT02465281

  Condition:   Stroke
  Intervention:   Other: Device: 3T scanner with MRI-compatible robot
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Predicting Rupture of Abdominal Aortic Aneurysm (AAA) by Anatomic and Hemodynamic Markers From In-vivo and In-vitro Imaging.

  NCT02463760

  Condition:   Aortic Aneurysm, Abdominal
  Intervention:   Other: Medical imaging
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Functional Connectivity In Relation To Proprioception and Sensorimotor Recovery in Stroke Patients (Feasibility Study)

  NCT02445768

  Condition:   Stroke
  Interventions:   Other: Cognitive multisensory rehabilitation;   Device: 3T scanner with MRI-compatible robot
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• MRI Technical Development and Applications in Kidney Disease

  NCT02421497

  Conditions:   Chronic Kidney Diseases;   Kidney Transplantation;   Dialysis;   Cognition Disorders
  Intervention:  
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Treatment of Chronic Itch in Atopic Dermatitis (Eczema)

  NCT02268448

  Condition:   Cutaneous Nerves CNS Itch
  Interventions:   Drug: Clonidine;   Drug: Naltrexone
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• The Effect of Chlorhexidine on the Oral and Lung Microbiota in Chronic Obstructive Pulmonary Disease

  NCT02252588

  Condition:   Chronic Obstructive Pulmonary Disease
  Interventions:   Drug: Chlorhexidine;   Other: Placebo
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Veterans Medical Research Foundation;   Flight Attendant Medical Research Institute
  Recruiting
• Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People

  NCT02191098

  Conditions:   HIV;   Stable ART
  Intervention:   Drug: ALT-803
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Dismantling the Components and Dosing of CBT for Co-Occurring Disorders

  NCT02161211

  Conditions:   CBT Decoupling;   CBT Anxiety Reduction;   CBT Combined
  Interventions:   Behavioral: De-coupling;   Behavioral: Anxiety Reduction;   Behavioral: Combined
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• DPCP for the Treatment of Alopecia Areata

  NCT03651752

  Condition:   Alopecia Areata
  Intervention:   Drug: Diphenylcyclopropenone (DPCP) Ointment
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   National Alopecia Areata Foundation
  Recruiting
• A Proactive Walking Trial to Reduce Pain in Black Veterans

  NCT01983228

  Condition:   Musculoskeletal Pain
  Intervention:   Behavioral: Intervention Condition
  Sponsor:   VA Office of Research and Development
  Recruiting
• Faith Based Pilot Intervention to Reduce Tobacco Use Among Somali Males

  NCT03379142

  Conditions:   Tobacco Use;   Faith-Based;   Community-engaged;   Text Messaging
  Intervention:   Behavioral: Faith-Based messages
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Spinal Cord Stimulation to Treat Hypertension

  NCT02828436

  Condition:   Hypertension
  Interventions:   Device: Precision Spectra System;   Behavioral: Exercise Intervention
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Liposomal Bupivacaine in One-level Instrumented Posterior Spinal Fusion

  NCT03745040

  Conditions:   Lumbar Spinal Stenosis;   Lumbar Disc Herniation;   Lumbar Disc Disease;   Lumbar Spondylolisthesis
  Intervention:   Drug: Liposomal bupivacaine
  Sponsors:   Allina Health System;   Twin Cities Spine Center
  Recruiting
• Termination Therapy for Ventricular Tachyarrhythmias

  NCT03093051

  Conditions:   Ventricular Fibrillation;   Ventricular Tachycardia
  Intervention:   Device: Unpinning Termination therapy
  Sponsors:   Cardialen, Inc.;   National Heart, Lung, and Blood Institute (NHLBI);   Washington University School of Medicine
  Recruiting
• Self-management of Sedative Therapy by Ventilated Patients

  NCT02819141

  Conditions:   Critical Illness;   Anxiety;   Respiratory Failure
  Intervention:   Drug: Dexmedetomidine
  Sponsors:   Mayo Clinic;   University of Minnesota, MN;   National Heart, Lung, and Blood Institute (NHLBI)
  Recruiting
• Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)

  NCT02583672

  Condition:   Gaucher Disease Type 1
  Intervention:   Drug: N-acetylcysteine
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Rare Diseases Clinical Research Network;   National Center for Advancing Translational Science (NCATS);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute of Neurological Disorders and Stroke (NINDS);   Lysosomal Disease Network
  Recruiting
• Study Of Drinks With Artificial Sweeteners in People With Type 2 Diabetes

  NCT03944616

  Condition:   Type 2 Diabetes
  Interventions:   Behavioral: Diet Beverage;   Behavioral: Water
  Sponsors:   University of California, Irvine;   University of Minnesota, MN;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Recruiting
• Point-of-Care Echocardiography With Assistance Technology

  NCT03897140

  Condition:   Cardiac Disease
  Intervention:   Diagnostic Test: Diagnostic Test: Limited Echocardiogram
  Sponsor:   Sara Guttas
  Recruiting
• Pioglitazone for the Treatment of Alcohol Use Disorder

  NCT03864146

  Condition:   Alcohol Use Disorder
  Intervention:   Behavioral: Brief Behavioral Compliance Enhancement Treatment
  Sponsor:   VA Office of Research and Development
  Recruiting
• Seven vs. 14 Days Treatment for Male Urinary Tract Infection

  NCT01994538

  Condition:   Urinary Tract Infections
  Interventions:   Other: Longer therapy duration;   Other: Shorter therapy duration
  Sponsor:   VA Office of Research and Development
  Recruiting
• Lung Volume Recruitment Combined With Expiratory Muscle Strength Training in ALS

  NCT03202017

  Condition:   Amyotrophic Lateral Sclerosis
  Interventions:   Procedure: Expiratory Muscle Strength Training (EMST);   Procedure: EMST + Lung Volume Recruitment (LVR)
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

  NCT01562626

  Conditions:   Tumors;   Neoplasms;   Cancer
  Interventions:   Drug: APS001F;   Drug: Flucytosine (5-FC);   Drug: 10% maltose
  Sponsor:   Anaeropharma Science, Inc.
  Recruiting
• Improving Outcome for Family Caregivers of Older Adults With Complex Conditions: The Adult Day Plus (ADS Plus) Program

  NCT02927821

  Condition:   Stress
  Intervention:   Behavioral: ADS Plus
  Sponsors:   Johns Hopkins University;   University of Minnesota - Clinical and Translational Science Institute;   National Institute on Aging (NIA)
  Recruiting
• Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability

  NCT02002819

  Condition:   Alzheimer's Disease
  Intervention:   Drug: levetiracetam
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Minnesota Adrenoleukodystrophy Registry Study (MARS) and Biobank

  NCT03789721

  Condition:   ALD (Adrenoleukodystrophy)
  Interventions:   Other: Medical Record Abstraction;   Other: Biospecimen Sample Collection
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• T Cell Receptor α/β TCD HCT in Patients With Fanconi Anemia

  NCT03579875

  Conditions:   Fanconi Anemia;   Severe Aplastic Anemia;   Myelodysplastic Syndromes
  Interventions:   Drug: Total Body Irradiation (TBI) (Plan 1);   Drug: Cyclophosphamide (CY) (Plan 1);   Drug: Fludarabine (FLU);   Drug: Methylprednisolone (MP);   Device: Donor mobilized PBSC infusion;   Drug: G-CSF;   Drug: Cyclophosphamide (CY) (Plan 2);   Drug: Rituximab
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Metabolism, Breastmilk, and Microbiome

  NCT03522597

  Conditions:   Obesity;   Diabetes, Gestational
  Intervention:  
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   University of Oklahoma;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  Recruiting
• International PPB/DICER1 Registry

  NCT03382158

  Conditions:   Pleuropulmonary Blastoma;   Sertoli-Leydig Cell Tumor;   DICER1 Syndrome;   Cystic Nephroma;   Wilms Tumor;   Pineoblastoma;   Renal Sarcoma;   Nodular Hyperplasia of Thyroid;   Nasal Chondromesenchymal Hamartoma;   Ciliary Body Medulloepithelioma;   Neuroblastoma;   Pituitary Cancer;   Embryonal Rhabdomyosarcoma
  Intervention:  
  Sponsors:   Children's Hospitals and Clinics of Minnesota;   Children's Research Institute;   Washington University School of Medicine;   ResourcePath, LLC;   Beijing Children's Hospital;   University of Cambridge;   Emory University;   Dana-Farber Cancer Institute
  Recruiting
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

  NCT03314974

  Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Lymphoma;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myeloproliferative Neoplasms;   Myelofibrosis;   Myelodysplasia;   Refractory Anemia;   High Risk Anemia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large Cell Non Hodgkins Lymphoma;   Lymphoblastic Lymphoma;   Burkitt Lymphoma;   High Grade Non-Hodgkin's Lymphoma, Adult;   Multiple Myeloma;   Juvenile Myelomonocytic Leukemia;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Natural Killer Cell Malignancies;   Acquired Bone Marrow Failure Syndromes
  Interventions:   Biological: HSCT with TBI Regimen;   Biological: HSCT with Non-TBI Regimen
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• Biology of Osteosarcoma (BOOST) Registry and Biobank

  NCT03225872

  Condition:   Osteosarcoma
  Intervention:  
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• The Impact of Tibial Tubercle-trochlear Groove Distance and Patellar Height on the Outcome of Isolated Medial Patellofemoral Ligament Reconstruction

  NCT03076008

  Condition:   Patellar Dislocation
  Intervention:   Other: Observational
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine;   Ohio State University;   OrthoSport Victoria
  Recruiting
• Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic

  NCT02988466

  Condition:   Hematologic Malignancies
  Interventions:   Biological: Haplo HCT <55 years old;   Biological: Haplo HCT ≥55 years old;   Drug: GVHD Prophylaxis;   Biological: Haplo HCT ≥55 and < 65 years old;   Biological: Haplo HCT ≥65 and ≤75 years old
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• New Ulm at HOME (Healthy Offerings Via the Mealtime Environment), NU-HOME

  NCT02973815

  Conditions:   Obesity, Childhood;   Physical Activity;   Food Intake;   Rural Health
  Intervention:   Behavioral: NU-HOME Intervention
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Allina Health System;   Minneapolis Heart Institute Foundation
  Recruiting
• Clinical Performance of a New Esthetic, Self-ligating Orthodontic Bracket

  NCT02959671

  Condition:   Malocclusion
  Intervention:   Device: Lower Anterior EXD-952 Self-ligating Brackets
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   3M Oral Care
  Recruiting
• Robot-aided Proprioceptive Rehabilitation Training

  NCT02565407

  Conditions:   Stroke;   Peripheral Sensory Neuropathy
  Interventions:   Behavioral: Proprioceptive training;   Behavioral: Usual care
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Gulf War Illness Inflammation Reduction Trial

  NCT02506192

  Conditions:   Chronic Inflammation;   Chronic Pain;   Fatigue;   Cognitive Impairment
  Interventions:   Drug: Delayed-Release Prednisone;   Drug: Placebo
  Sponsors:   Minneapolis Veterans Affairs Medical Center;   United States Department of Defense
  Recruiting
• International Ovarian & Testicular Stromal Tumor Registry

  NCT01970696

  Conditions:   Ovarian Stromal Tumor;   Testicular Stromal Tumors;   Ovarian Small Cell Carcinoma;   DICER1 Gene Mutation
  Intervention:  
  Sponsors:   Children's Hospitals and Clinics of Minnesota;   Children's Research Institute;   Dana-Farber Cancer Institute;   Washington University School of Medicine;   University of Texas Southwestern Medical Center;   M.D. Anderson Cancer Center;   Children's Hospital Colorado;   Rutgers University;   Massachusetts General Hospital;   Klinikum Dortmund Wirbelsäulenchirurgie;   ResourcePath, LLC
  Recruiting
• Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries

  NCT01166009

  Conditions:   Autologous Stem Cell Transplantation;   Allogeneic Stem Cell Transplantation;   Solid Tumors;   Blood Cancers
  Intervention:  
  Sponsor:   Center for International Blood and Marrow Transplant Research
  Recruiting
• University of Minnesota Transplant Registry

  NCT01062581

  Conditions:   Transplant Recipient;   Transplant Donation
  Intervention:  
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• A Natural History Study of the Gangliosidoses

  NCT00668187

  Conditions:   Tay-Sachs Disease;   Sandhoff Disease;   Late Onset Tay-Sachs Disease;   GM1 Gangliosidosis;   GM2 Gangliosidosis
  Intervention:  
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Rare Diseases Clinical Research Network;   National Center for Advancing Translational Science (NCATS);   National Institute of Neurological Disorders and Stroke (NINDS);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Lysosomal Disease Network
  Recruiting
• Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study

  NCT01581424

  Condition:   Fabry Disease
  Intervention:  
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Rare Diseases Clinical Research Network;   National Center for Advancing Translational Science (NCATS);   National Institute of Neurological Disorders and Stroke (NINDS);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Washington University School of Medicine;   Haukeland University Hospital
  Recruiting
• Alport Syndrome Treatments and Outcomes Registry

  NCT00481130

  Condition:   Alport Syndrome
  Intervention:  
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors

  NCT00432094

  Conditions:   Childhood Germ Cell Tumor;   Ovarian Cancer;   Teratoma
  Interventions:   Drug: carboplatin;   Drug: etoposide;   Drug: ifosfamide;   Drug: paclitaxel;   Drug: thiotepa;   Procedure: autologous hematopoietic stem cell transplantation;   Drug: Mesna;   Biological: filgrastim
  Sponsor:   Masonic Cancer Center, University of Minnesota
  Recruiting
• A Test-Drive Strategy for the Prescription of Prosthetic Feet for People With Leg Amputations

  NCT03651830

  Condition:   Amputation
  Interventions:   Device: Prosthetic Foot Emulator;   Device: Commercially available prosthetic feet
  Sponsors:   Seattle Institute for Biomedical and Clinical Research;   VA Puget Sound Health Care System;   Minneapolis Veterans Affairs Medical Center;   Brooke Army Medical Center;   Stanford University;   University of Washington
  Recruiting
• FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

  NCT03841110

  Conditions:   Advanced Solid Tumors;   Lymphoma;   Gastric Cancer;   Colorectal Cancer;   Head and Neck Cancer;   Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Pancreas Cancer;   Melanoma;   NSCLC;   Urothelial Carcinoma;   Cervical Cancer;   Microsatellite Instability;   Merkel Cell Carcinoma
  Interventions:   Drug: FT500;   Drug: Nivolumab;   Drug: Pembrolizumab;   Drug: Atezolizumab;   Drug: Cyclophosphamide;   Drug: Fludarabine
  Sponsor:   Fate Therapeutics
  Recruiting
• EKG Criteria and Identification of Acute Coronary Occlusion

  NCT03863327

  Conditions:   Acute Coronary Syndrome;   STEMI;   STEMI - ST Elevation Myocardial Infarction;   Acute Coronary Artery Thrombosis (Diagnosis);   NSTEMI - Non-ST Segment Elevation MI;   Non-ST Elevation Myocardial Infarction;   Non ST Segment Elevation Myocardial Infarction;   Non ST Segment Elevation Acute Coronary Syndrome;   Non-ST Elevation Myocardial Infarction (nSTEMI);   Non STEMI
  Intervention:   Other: No intervention
  Sponsors:   Stony Brook University;   Hennepin County Medical Center, Minneapolis
  Recruiting
• Stories for Change: Digital Storytelling for Diabetes Self-Management Among Hispanic Adults

  NCT03766438

  Condition:   Type2 Diabetes
  Intervention:   Behavioral: Digital Storytelling Intervention
  Sponsors:   Mayo Clinic;   Hennepin Healthcare, Minneapolis, MN;   Mountain Park Health Center - Phoenix, AZ;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  Recruiting
• Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

  NCT03732950

  Conditions:   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Intervention:   Biological: Pembrolizumab
  Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
  Recruiting
• ACTH in Progressive Forms of MS

  NCT01950234

  Conditions:   Secondary Progressive Multiple Sclerosis;   Primary Progressive Multiple Sclerosis;   Progressive Relapsing Multiple Sclerosis
  Interventions:   Drug: ACTH;   Drug: Placebo
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Mallinckrodt
  Recruiting
• Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace

  NCT03272685

  Conditions:   Tobacco Smoking;   Nicotine Dependence
  Interventions:   Drug: Very Low Nicotine Content Cigarettes;   Drug: Normal Nicotine Content Cigarettes
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Duke University;   University of California, San Francisco
  Recruiting
• Sacral Nerve Stimulation in Improving Bladder After Acute Traumatic Spinal Cord Injury

  NCT03083366

  Conditions:   Spinal Cord Injury, Acute;   Neurogenic Bladder;   Incontinence;   Urinary Tract Infections
  Intervention:   Device: PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
  Sponsors:   University of Utah;   University of Minnesota - Clinical and Translational Science Institute;   University of Michigan
  Recruiting
• Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation

  NCT03663933

  Conditions:   Lymphoproliferative Disorders;   Autoimmune Lymphoproliferative;   Primary T-cell Immunodeficiency Disorders;   Immune System Diseases;   Common Variable Immunodeficiency
  Interventions:   Drug: Immunosuppression Only Conditioning (IOC);   Drug: Reduced Intensity Conditioning (RIC);   Drug: GVHD Prophylaxis;   Procedure: Allogeneic HSC
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Improving Veteran Adherence to Treatment for PTSD Through Partnering With Families

  NCT03256227

  Condition:   Posttraumatic Stress Disorder
  Interventions:   Behavioral: Family Supported Prolonged Exposure;   Behavioral: Standard Prolonged Exposure
  Sponsor:   VA Office of Research and Development
  Recruiting
• Aging and Cognitive Health Evaluation in Elders (ACHIEVE)

  NCT03243422

  Conditions:   Aging;   Cognitive Decline
  Interventions:   Other: Successful aging education intervention;   Other: Hearing intervention
  Sponsors:   Johns Hopkins Bloomberg School of Public Health;   University of North Carolina;   University of South Florida;   University of Pittsburgh;   University of Mississippi Medical Center;   Wake Forest University;   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• A Phase 1 Study to Evaluate SNDX- 6352 in Subjects With Active cGVHD

  NCT03604692

  Condition:   Chronic Graft-versus-host-disease
  Intervention:   Drug: SNDX-6352
  Sponsor:   Syndax Pharmaceuticals
  Recruiting
• A Study of CNSA-001 in Primary Tetrahydrobiopterin Deficient Patients With Hyperphenylalaninemia

  NCT03519711

  Conditions:   BH4 Deficiency;   Hyperphenylalaninemia, Non-Phenylketonuric
  Intervention:   Drug: CNSA-001
  Sponsor:   Censa Pharmaceuticals, Inc.
  Recruiting
• Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

  NCT03272217

  Condition:   Urothelial Carcinoma
  Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
  Sponsors:   Arjun Balar, MD;   Roche-Genentech;   Hoosier Cancer Research Network
  Recruiting
• A Registry of Patients With Primary Choroidal Melanoma (CM) or Indeterminate Lesions (ILs)

  NCT03941379

  Conditions:   Choroidal Melanoma;   Indeterminate Lesions of Eye
  Intervention:  
  Sponsor:   Aura Biosciences
  Recruiting
• walk2Wellness: Long-term Effects of Walkasins® Wearable Sensory Prosthesis

  NCT03538756

  Conditions:   Sensory Peripheral Neuropathy;   Balance; Distorted;   Sensation Disorders
  Intervention:   Device: walkasins
  Sponsor:   RxFunction Inc.
  Recruiting
• FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

  NCT03319459

  Conditions:   HER2 Positive Gastric Cancer;   Colorectal Cancer;   Head and Neck Squamous Cell Carcinoma;   EGFR Positive Solid Tumor;   Advanced Solid Tumors;   HER2-positive Breast Cancer;   Hepatocellular Carcinoma;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Pancreas Cancer
  Interventions:   Drug: FATE-NK100;   Drug: Cetuximab;   Drug: Trastuzumab
  Sponsor:   Fate Therapeutics
  Recruiting
• Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

  NCT03300557

  Conditions:   Atypical Hyperplasia;   Endometrial Intraepithelial Neoplasia;   FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma;   Postmenopausal
  Interventions:   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Other: Pharmacokinetic Study;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Treating Comorbid Pain and Depression in HIV+ Individuals

  NCT02766751

  Conditions:   HIV;   Depression;   Pain
  Interventions:   Behavioral: HIVPASS;   Behavioral: Health Education
  Sponsor:   Butler Hospital
  Recruiting
• Trial Comparing Relapse Rates Between Standard Ureteroscopic Removal Of Ureteral Stone And Standard Removal With Additional Ureterorenic Clearing Of Non-Symptomatic Stones In The Kidney

  NCT02210650

  Condition:   Ureteral Stones
  Interventions:   Procedure: Ureteral stone removal;   Procedure: Asymptomatic kidney stones and ureteral stone removed
  Sponsors:   Indiana Kidney Stone Institute;   University of Washington Medical Center Department of Urology (Seattle, WA);   VA Puget Sound Health Care System
  Recruiting
• Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

  NCT03681561

  Condition:   Hodgkin Lymphoma
  Interventions:   Drug: Ruxolitinib;   Drug: Nivolumab
  Sponsors:   Veronika Bachanova;   Incyte Corporation;   Bristol-Myers Squibb
  Recruiting
• Pelvital Stress Urinary Incontinence Training Device: P-SUIT

  NCT02954042

  Condition:   Incontinence
  Interventions:   Device: Pelvital probe;   Device: Placebo Probe
  Sponsor:   University of Minnesota - Clinical and Translational Science Institute
  Recruiting
• Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

  NCT02900560

  Condition:   Epithelial Ovarian Cancer
  Interventions:   Drug: CC-486;   Biological: Pembrolizumab
  Sponsors:   Translational Research in Oncology;   Celgene
  Recruiting
• Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer

  NCT02876640

  Conditions:   Early-Stage Breast Carcinoma;   Invasive Breast Carcinoma
  Interventions:   Drug: Retinoid 9cUAB30;   Procedure: Therapeutic Conventional Surgery
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• CoQ10 in Gulf War Illness

  NCT02865460

  Conditions:   Gulf War Illness;   Chronic Fatigue;   Ubiquinol;   Coenzyme Q10
  Interventions:   Drug: Ubiquinol;   Drug: Placebo
  Sponsor:   VA Office of Research and Development
  Recruiting
• Low InTensity Exercise Intervention in PAD

  NCT02538900

  Condition:   Peripheral Artery Disease
  Interventions:   Behavioral: Exercise;   Other: Attention control
  Sponsors:   Northwestern University;   National Heart, Lung, and Blood Institute (NHLBI)
  Recruiting
• Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

  NCT03502746

  Condition:   Mesothelioma, Malignant
  Interventions:   Drug: Nivolumab;   Drug: Ramucirumab
  Sponsors:   Arkadiusz Z. Dudek, MD;   HealthPartners Institute Regions Cancer Care Center;   Eli Lilly and Company;   Bristol-Myers Squibb
  Recruiting
• Psychosocial Rehabilitation After Moral Injury and Loss With Adaptive Disclosure

  NCT03056157

  Conditions:   Post-traumatic Stress Disorder;   Moral Injury;   Traumatic Loss
  Interventions:   Behavioral: Adaptive Disclosure for Moral Injury and Loss;   Behavioral: Present Centered Therapy
  Sponsors:   VA Office of Research and Development;   Minneapolis Veterans Affairs Medical Center;   San Francisco Veterans Affairs Medical Center;   San Diego Veterans Healthcare System
  Recruiting
• Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

  NCT02867384

  Condition:   Graft vs. Host Disease
  Interventions:   Drug: Obinutuzumab;   Drug: Placebo
  Sponsors:   Dana-Farber Cancer Institute;   Roche-Genentech
  Recruiting
• Mindful Movement for Physical Activity and Wellbeing in Older Adults- A Hybrid Effectiveness-Implementation Study

  NCT03929393

  Conditions:   Physical Inactivty;   Wellbeing;   Mindfulness
  Interventions:   Behavioral: Mindful Movement;   Other: Keys to Health & Wellbeing
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   YMCA
  Recruiting
• Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Older Patients With Untreated Chronic Lymphocytic Leukemia

  NCT03737981

  Condition:   Chronic Lymphocytic Leukemia
  Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Observation;   Drug: Venetoclax
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

  NCT03633331

  Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2/Neu Negative;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Dried Blood Spot Testing of CMV Detection in HCT Recipients

  NCT03910478

  Condition:   Cytomegalovirus Infection
  Interventions:   Device: DBS Self-Collection Kit;   Other: Standard Control Strategy
  Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
  Recruiting
• Diuretic Comparison Project

  NCT02185417

  Condition:   Hypertension
  Interventions:   Drug: Hydrochlorothiazide (HCTZ);   Drug: Chlorthalidone
  Sponsor:   VA Office of Research and Development
  Recruiting
• Mepo for EoE Study

  NCT03656380

  Conditions:   EoE;   Eosinophilic Esophagitis
  Interventions:   Drug: Mepolizumab 300 mg;   Drug: Mepolizumab 100 mg;   Other: Placebo
  Sponsors:   University of North Carolina, Chapel Hill;   GlaxoSmithKline;   University of Utah;   Northwestern University;   Minnesota Gastroenterology, P.A.
  Recruiting
• QUILT-3.002: ALT-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

  NCT02384954

  Condition:   Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
  Interventions:   Biological: Rituximab;   Biological: ALT-803
  Sponsor:   Altor BioScience
  Recruiting
• RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort)

  NCT03584464

  Condition:   Coronary Artery Disease
  Intervention:   Device: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
  Sponsor:   Medtronic Vascular
  Recruiting
• Adenosine Contrast CorrELations in Evaluating RevAscularizaTION

  NCT03557385

  Condition:   Percutaneous Coronary Intervention
  Interventions:   Drug: Iopamidol;   Drug: adenosine;   Device: Navvus® Catheter;   Device: CVi® Contrast Delivery System
  Sponsors:   Duke University;   Acist Medical Systems
  Recruiting
• Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

  NCT02396134

  Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Hodgkin Lymphoma;   Adult Non-Hodgkin Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegaloviral Infection;   Hematopoietic and Lymphoid Cell Neoplasm;   HLA-A*0201 Positive Cells Present;   Myelodysplastic Syndrome;   Adult Lymphoblastic Lymphoma;   Chronic Lymphocytic Leukemia;   Myelofibrosis;   Myeloproliferative Neoplasm
  Interventions:   Biological: CMVpp65-A*0201 peptide vaccine;   Other: Placebo;   Other: Laboratory Biomarker Analysis
  Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
  Recruiting
• A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome

  NCT03703908

  Condition:   Focal Segmental Glomerulosclerosis
  Intervention:   Drug: CCX140-B
  Sponsor:   ChemoCentryx
  Recruiting
• Phase II Trial of Continuation Therapy in Advanced NSCLC

  NCT03083808

  Condition:   Non-Small-Cell Lung Cancer
  Intervention:   Drug: Pembrolizumab
  Sponsors:   Greg Durm, MD;   Merck Sharp & Dohme Corp.;   Big Ten Cancer Research Consortium
  Recruiting
• Wellclub Shoulder Therapy Outcome Validation

  NCT02954185

  Condition:   Shoulder Pain
  Interventions:   Device: WellClub;   Behavioral: Standard Therapy
  Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Fairview Sports Physical Therapy Program
  Recruiting
• Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

  NCT03087708

  Conditions:   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
  Interventions:   Drug: Naloxegol;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia

  NCT03701282

  Conditions:   CCND1/IGHG1 Fusion Negative;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   t(11;14) Negative
  Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Drug: Venetoclax
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

  NCT03578081

  Condition:   Malignant Neoplasm
  Interventions:   Drug: Palonosetron Hydrochloride;   Drug: Ondansetron Hydrochloride;   Drug: Dexamethasone;   Drug: Fosaprepitant Dimeglumine;   Drug: Olanzapine;   Other: Placebo
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  NCT02912559

  Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

  NCT02595944

  Conditions:   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Intervention:   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992

  Conditions:   ALK Gene Rearrangement;   ALK Gene Translocation;   ALK Positive;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   ALK Gene Rearrangement;   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly

  NCT02121158

  Conditions:   Cardiomyopathy;   Coronary Artery Disease;   Congestive Heart Failure;   Myocardial Infarction
  Interventions:   Device: Implantable Cardioverter Defibrillator;   Other: Optimal Medical Therapy
  Sponsor:   VA Office of Research and Development
  Recruiting
• Bupropion in Reducing Cancer Related Fatigue in Stage I-III Breast Cancer Survivors

  NCT03996265

  Conditions:   Anatomic Stage I Breast Cancer AJCC v8;   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage IB Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Cancer Fatigue;   Cancer Survivor;   Complete Remission;   Prognostic Stage I Breast Cancer AJCC v8;   Prognostic Stage IA Breast Cancer AJCC v8;   Prognostic Stage IB Breast Cancer AJCC v8;   Prognostic Stage II Breast Cancer AJCC v8;   Prognostic Stage IIA Breast Cancer AJCC v8;   Prognostic Stage IIB Breast Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8
  Interventions:   Drug: Bupropion Hydrochloride Controlled-release;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Gary Morrow;   National Cancer Institute (NCI)
  Recruiting
• Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

  NCT03971474

  Conditions:   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Interventions:   Drug: Docetaxel;   Drug: Gemcitabine;   Drug: Gemcitabine Hydrochloride;   Biological: Pembrolizumab;   Drug: Pemetrexed;   Drug: Pemetrexed Disodium;   Biological: Ramucirumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Tenofovir Alafenamide in Preventing Liver Complications in Participants With Current or Past Hepatitis B Virus Who Are Receiving Anti-Cancer Therapy for Solid Tumors

  NCT03887702

  Conditions:   Hepatitis B Virus Positive;   Malignant Solid Neoplasm
  Interventions:   Other: Best Practice;   Other: Laboratory Biomarker Analysis;   Drug: Tenofovir Alafenamide
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382

  Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Bone Lesion;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Rich Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

  NCT03839940

  Condition:   Malignant Neoplasm
  Interventions:   Drug: Dexamethasone;   Other: Placebo;   Other: Questionnaire;   Other: Quality-of-Life Assessment;   Drug: Everolimus
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Testing Maintenance Immunotherapy Versus Observation in Patients With Oropharynx Cancer

  NCT03811015

  Conditions:   Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Human Papillomavirus-16 Positive;   Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Smoker
  Interventions:   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Biological: Nivolumab;   Other: Patient Observation
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Firstline Pembrolizumab Alone or in Combination With Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients With Stage IV Non-squamous Non-small Cell Lung Cancer

  NCT03793179

  Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   PD-L1 Positive;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
  Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Nivolumab and Ipilimumab Followed by Nivolumab Versus Cabozantinib and Nivolumab in Treating Patients With Metastatic Untreated Renal Cell Cancer

  NCT03793166

  Conditions:   Clear Cell Renal Cell Carcinoma;   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Malignant Neoplasm in the Viscera;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer AJCC v8
  Interventions:   Drug: Cabozantinib;   Biological: Ipilimumab;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414

  Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
  Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)

  NCT03737994

  Conditions:   ALK Gene Rearrangement;   ALK Positive;   Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Interventions:   Drug: Alectinib;   Drug: Brigatinib;   Drug: Carboplatin;   Drug: Ceritinib;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Ensartinib;   Drug: Lorlatinib;   Drug: Pemetrexed
  Sponsors:   National Cancer Institute (NCI);   NRG Oncology
  Recruiting
• Pembrolizumab Compared to Standard of Care Observation in Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer

  NCT03712605

  Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8;   Resected Mass
  Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Genetic Analysis of Blood and Tissue Samples From Participants With Advanced Cancer

  NCT03707574

  Conditions:   Advanced Melanoma;   Advanced Renal Cell Carcinoma;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8;   Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Prognostic Stage IV Breast Cancer AJCC v8;   Stage III Colorectal Cancer AJCC v8;   Stage III Lung Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Prostate Cancer AJCC v8;   Stage IIIA Colorectal Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Prostate Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Prostate Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Prostate Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8
  Intervention:   Procedure: Biospecimen Collection
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

  NCT03701308

  Condition:   Acute Myeloid Leukemia
  Interventions:   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Uproleselan
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery

  NCT03698019

  Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
  Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

  NCT03694002

  Conditions:   Locally Advanced Thymic Carcinoma;   Metastatic Thymic Carcinoma;   Recurrent Thymic Carcinoma;   Unresectable Thymic Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Ramucirumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia

  NCT03654768

  Condition:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Nilotinib;   Drug: Ruxolitinib Phosphate
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Gemcitabine Hydrochloride and Cisplatin in Treating Participants With Invasive Bladder Urothelial Cancer

  NCT03609216

  Conditions:   Infiltrating Bladder Urothelial Carcinoma;   Stage II Bladder Urothelial Carcinoma;   Stage III Bladder Urothelial Carcinoma
  Interventions:   Drug: Gemcitabine Hydrochloride;   Drug: Cisplatin;   Biological: Pegfilgrastim;   Procedure: Conventional Surgery;   Procedure: Radical Cystectomy;   Other: Chemoradiotherapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

  NCT03499808

  Conditions:   Amorphous, Eosinophilic, and Acellular Deposit;   Constipation;   Diarrhea;   Early Satiety;   Gastrointestinal Hemorrhage;   Hepatomegaly;   Lymphadenopathy;   Macroglossia;   Nausea;   Primary Systemic Amyloidosis;   Purpura;   Recurrent Primary Amyloidosis;   Refractory Primary Amyloidosis
  Interventions:   Biological: Isatuximab;   Other: Laboratory Biomarker Analysis
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

  NCT03475186

  Conditions:   Glioblastoma;   Radiotherapy; Complications;   Cognitive Decline;   Chemoradiation
  Intervention:   Drug: Ramipril
  Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
  Recruiting
• Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223

  Condition:   Acute Coronary Syndrome
  Interventions:   Biological: Apolipoprotein A-I [human] (apoA-I);   Other: Placebo
  Sponsor:   CSL Behring
  Recruiting
• S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer

  NCT03418961

  Conditions:   Cardiotoxicity;   HER2/Neu Positive;   Metastatic Malignant Neoplasm in the Brain;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Carvedilol;   Other: Laboratory Biomarker Analysis;   Other: Patient Observation
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

  NCT03414970

  Conditions:   Ductal Breast Carcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma;   Medullary Breast Carcinoma;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Tubular Breast Carcinoma
  Interventions:   Radiation: Radiation Therapy;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis;   Radiation: Hypofractionated Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

  NCT03375320

  Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Digestive System Neuroendocrine Neoplasm;   Functioning Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Neuroendocrine Neoplasm;   Non-Functioning Pancreatic Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor;   Serotonin-Producing Pancreatic Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
  Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• BIOMARKER TRIAL of APALUTAMIDE and RADIATION for RECURRENT PROSTATE CANCER

  NCT03371719

  Conditions:   PSA Progression;   Stage III Prostate Adenocarcinoma;   Stage IV Prostate Adenocarcinoma
  Interventions:   Drug: Apalutamide;   Radiation: External Beam Radiation Therapy;   Other: Placebo
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

  NCT03330405

  Condition:   Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
  Interventions:   Drug: Avelumab Phase 1b;   Drug: Talazoparib Phase 1b;   Drug: Avelumab Phase 2;   Drug: Talazoparib Phase 2
  Sponsor:   Pfizer
  Recruiting